Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 7;15(11):1365.
doi: 10.3390/ph15111365.

A Review of the Safety of Interleukin-17A Inhibitor Secukinumab

Vishnu Eshwar  1 , Ashwin Kamath  1 , Rajeshwari Shastry  1 , Ashok K Shenoy  1 , Priyanka Kamath  1
Affiliations
Review

A Review of the Safety of Interleukin-17A Inhibitor Secukinumab

Vishnu Eshwar et al. Pharmaceuticals (Basel). .

Abstract

Secukinumab is an anti-interleukin (IL)-17A IgG1-κ monoclonal antibody approved for psoriasis, psoriatic arthritis, and ankylosing spondylitis. Its efficacy is well documented, but the complete safety profile of secukinumab, especially on long-term use, needs to be studied. IL-17 inhibitors increase the risk of infections, especially respiratory tract infections and candidiasis, and inflammatory bowel disease; the causal relationships are well described. However, evidence regarding the other adverse events is scarce, and causal associations between the adverse events and the biologic remain unresolved. This review aims to present a narrative perspective on the safety of secukinumab and identify some key areas where the safety of secukinumab may potentially be useful in understanding the scope of secukinumab therapy and making informed clinical decisions.

Keywords: adverse event; inflammatory bowel disease; interleukin 17; psoriasis; secukinumab.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Physiological and immunological functions of IL-17A [6,7].
Figure 2
Figure 2
Potential adverse effects of secukinumab.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., Wang Y., Hood L., Zhu Z., Tian Q., et al. A Distinct Lineage of CD4 T Cells Regulates Tissue Inflammation by Producing Interleukin 17. Nat. Immunol. 2005;6:1133. doi: 10.1038/ni1261. - DOI - PMC - PubMed
    1. Adams R., Maroof A., Baker T., Lawson A.D.G., Oliver R., Paveley R., Rapecki S., Shaw S., Vajjah P., West S., et al. Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F. Front. Immunol. 2020;11:1894. doi: 10.3389/fimmu.2020.01894. - DOI - PMC - PubMed
    1. Miossec P., Korn T., Kuchroo V.K. Interleukin-17 and Type 17 Helper T Cells. N. Engl. J. Med. 2009;361:888–898. doi: 10.1056/NEJMra0707449. - DOI - PubMed
    1. Khader S., Das S. Yin and Yang of Interleukin-17 in Host Immunity to Infection. F1000Research. 2017;6:741. doi: 10.12688/F1000RESEARCH.10862.1. - DOI - PMC - PubMed
    1. Blake S.J., Teng M.W.L. Role of IL-17 and IL-22 in Autoimmunity and Cancer. Actas Dermosifiliogr. 2014;105((Suppl. 1)):41–50. doi: 10.1016/S0001-7310(14)70017-1. - DOI - PubMed